Similar Items: Primary immune trajectories following a single BNT162b2 vaccination scheme in SARS-CoV-2–naïve individuals
- Seroprevalence of anti-SARS-CoV-2 specific antibodies in vaccinated and vaccine naïve adult Nigerians
- Serological profile of naïve patients affected by the first sars-cov-2 variant: A prospective study
- Multi Epitope-Based Vaccine Design for Protection Against Mycobacterium tuberculosis and SARS-CoV-2 Coinfection
- Detection of spike protein in term placentas of COVID-19 vaccinated and/or SARS-CoV-2 infected women
- Polymyalgia Rheumatica Post-SARS-CoV-2 Infection
- Durability of the BNT162b2 XBB:1.5-adapted vaccine against JN.1 hospitalisation in Europe, October 2023 to August 2024: A test-negative case-control study using the id.DRIVE platform